|
HS Code |
892822 |
| name | Clonixic Acid |
| CAS_number | 1177-59-5 |
| molecular_formula | C16H13ClN2O4 |
| molecular_weight | 332.74 g/mol |
| appearance | White to off-white crystalline powder |
| solubility_in_water | Slightly soluble |
| melting_point | 206-208°C |
| pharmacological_class | Non-steroidal anti-inflammatory drug (NSAID) |
| route_of_administration | Oral |
| half_life | 4-6 hours |
| indications | Pain, inflammation, and dysmenorrhea |
| storage_conditions | Store at room temperature, protected from moisture and light |
| mechanism_of_action | Inhibits prostaglandin synthesis via cyclooxygenase inhibition |
As an accredited Clonixic Acid factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Clonixic Acid, 25g, supplied in a sealed amber glass bottle with tamper-evident cap and clear labeling for laboratory use. |
| Shipping | Clonixic Acid is shipped in tightly sealed containers to ensure stability and prevent contamination. It is transported as a non-hazardous chemical under standard ambient conditions. The packaging complies with regulatory requirements, protecting the product from moisture, light, and mechanical damage during transit. Proper labeling ensures safe handling and traceability. |
| Storage | Clonixic Acid should be stored in a tightly sealed container, protected from light and moisture. Keep it in a cool, dry place, ideally at room temperature (20–25°C). Ensure the area is well-ventilated and free from sources of ignition or incompatible substances. Always follow local regulations and safety guidelines for chemical storage to maintain its stability and prevent degradation. |
Applications of Clonixic Acid in Industrial ManufacturingClonixic acid, produced at our dedicated synthesis facilities, supports several key industrial sectors. Our advanced production lines supply this raw material in accordance with strict quality and regulatory requirements to leading manufacturers around the globe. The following sections outline its primary industrial applications, including regulatory guidance, recommended formulation ratios, integration in downstream processes, and corresponding finished goods. 1. Pharmaceutical Formulations for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)Major global pharmaceutical companies use clonixic acid as a core active pharmaceutical ingredient (API) in the formulation of specific non-steroidal anti-inflammatory drugs. Manufacturers integrate this compound following approved pharmacopeial standards, with routine analytical QC for purity and identity. Integration occurs at the API synthesis or direct tablet granulation stage, depending on the desired dosage form. The resulting medicinal products address acute pain and inflammation in both outpatient and hospital settings. Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
2. Veterinary Pharmaceutical PreparationsAnimal health product manufacturers employ clonixic acid as an analgesic and anti-inflammatory agent in veterinary drugs for livestock and companion animals. Industrial scale production lines formulate premix powders, injectable solutions, and oral suspensions for compliance with regional veterinary drug standards. Material handling and batch traceability conform to specific veterinary pharmacopoeias and rigorous residue control protocols. Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
3. Research-Grade Chemical Reference StandardsContract research and academic laboratories use clonixic acid as a validated reference standard for drug metabolism, pharmacokinetics, and quality control method development. We manufacture high-purity batches tailored for analytical calibrators, internal standards, and trace analytical test development. Documentation and lot release adhere to international guidelines for chemical reference material production. Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
4. Bulk API for Contract Manufacturing Organizations (CMOs)Contract manufacturing organizations and toll processors procure clonixic acid in bulk quantities for incorporation into large-scale drug production campaigns on behalf of innovator and generic firms. Our supply chain supports detailed documentation, advanced analytical certificates, and full lot traceability. Processing adapts to each client’s specific blend, ensuring ingredient integrity and documentation flow from raw material intake through final fill-finish operations. Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
5. Clinical Trial Investigational Medicinal Products (IMP)Clinical research organizations source clonixic acid under Investigational Medicinal Product (IMP) regulations, incorporating it into blinded or open-label dosage forms for Phase I–III trials. Our IMP-grade lots support validated batch records, harmonized documentation to ICH guidelines, and full adverse event traceability. Release process includes lot-specific CoAs, stability data, and blinding codes as required by each study protocol. Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
|
Competitive Clonixic Acid prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615371019725 or mail to admin@sinochem-nanjing.com.
We will respond to you as soon as possible.
Tel: +8615371019725
Email: admin@sinochem-nanjing.com
Flexible payment, competitive price, premium service - Inquire now!
Years of manufacturing Clonixic Acid have taught us to pay attention to what actually happens beyond technical datasheets. It’s not just a pile of white powder coming off a line. Every batch is shaped by experience, operator skill, and a commitment to purity that doesn’t bend. If you ask anyone working within a true chemical production facility, they’ll tell you a product’s reputation is built one drum at a time. We’ve watched Clonixic Acid change from a specialty molecule almost nobody noticed to an important backbone in pharmaceutical research, development, and even finished dosage manufacturing. That journey has carried practical lessons no brochure captures.
Often, conversations about pharmaceutical actives focus on certificates and testing standards. Those have their place. But real results on the customer’s end depend on day-to-day attention to reliable crystallization, batch consistency, and exact control of impurities. Our factory staff talks about these topics over break-room coffee, not just in quarterly meetings. When we produce Clonixic Acid—Model CA-99, showing average assay values above 99 percent—the process reflects the discipline learned from repeated trials. We don’t just review certificates. We listen when a formulator tells us a sudden shift in particle characteristics throws off their blending or tableting lines. Lessons from these exchanges trickle down to our practices.
Some differences only reveal themselves when Clonixic Acid is used in real-world tablet presses or R&D labs. We keep lines open with downstream users, learning how dusting, static, and particle size influence line yield or product recovery. Our product shows trace impurity profiles well below recognized pharmacopeial limits. These details result directly from equipment recalibration schedules and batch tracking developed through years of small mishaps and incremental tweaks.
Differences matter once the material leaves our doors. There’s a world of variation between Clonixic Acid made with over-aged solvent or outdated crystallizer seals and the batches we release with tight control from raw material to finished packaging. Here, practical QA means every drum, not just random batches, gets the same physical and chemical evaluation. Some facilities chase speed. We learned it pays to slow down at critical cleaning junctions so the next lot isn’t contaminated by a rogue molecular cousin. You discover this value only after seeing real customer effects—never only from theory.
Every formulator faces challenges turning raw actives into robust, shelf-stable medicines. We see those problems up close. Particle flow, compaction, and solubility often draw more worry than what fits into classic specification sheets. That’s why we routinely discuss observations from customer pilot runs with our technical team, especially when changing mesh size or bulk density by a few percent ripples through their granulation lines. Our Clonixic Acid achieves minimal agglomeration tendencies. Reproducible particle morphology and low moisture absorption shown by CA-99 make direct compressing and wet granulation less troublesome. These aren’t marketing slogans—they’re results ground into practice after trouble-shooting dozens of real-world scale-ups.
Labs focusing on injectable formulations want material that dissolves rapidly, with minimal extraneous particulates. Tablet manufacturers report fewer capping and lamination events when sourcing from our lines versus lower-cost imports. Reasons trace back to the tolerance given during drying cycles and cooling rate control on our shop floor. These sound like small process steps, but they define the outcome more than post-production “polishing.”
Risk of contamination haunts every chemical producer. We’ve felt the sting of a rejected shipment when a seemingly minor solvent carryover slipped into product earlier in our history. Today, our processes for Clonixic Acid employ multi-step organic synthesis, including repeated solvent recovery, phase separation, and fine filtration—developed side by side with experienced operators who saw what failed in prior campaigns. We test not only for identified impurities but also for potential unlisted byproducts flagged by our own internal long-term monitoring. These safeguards come from direct lessons learned through decades, not just textbook best practices.
Our in-house lab, equipped with HPLC and GC instruments, isn’t just for show. Each technician tracks how even the ambient temperature or line start-up sequence can impact trace contaminant profiles. We empower production teams to call time-outs in the middle of a campaign if anything unusual surfaces. That level of control and involvement reduces the risk our customers face with downstream recalls, repeat analysis, or compliance audits. It also means tighter batch-to-batch reproducibility and build confidence in every shipment of Clonixic Acid—something only achieved by focusing equally on people and technology.
Pharmaceutical producers like us do not see regulatory frameworks as hurdles we reluctantly clear. Instead, Good Manufacturing Practice forms part of our operating reflex. Before regulators ever point out a control problem, we have likely argued about it in a heated production meeting and fixed it ourselves. When customers request data packs or traceability reports on Clonixic Acid CA-99, the full audit trail gets served up directly from our batch logs. Sifting through data, production teams can walk a visitor through raw material sourcing, process conditions, and package integrity tests as if showing family photos.
This hands-on compliance mindset ends up saving customers time, trouble, and sometimes their reputation. For finished drug producers facing increasingly strict health authority audits in places like the EU or North America, every active they source needs to bring ironclad traceability. Our approach doesn’t wait for new rules to land. We have lost sleep over the smallest inconsistencies, even ones invisible to inspectors. If a single flask or holding tank sees unusual conditions, we segregate that batch, check it twice, and only release it with manager sign-off. Our goal is always zero recalls.
Producing Clonixic Acid is not just about chemistry; it’s about protecting rights—ours and those of our customers. Our patent monitoring group routinely evaluates changes in the intellectual property landscape for both the molecule and analogous process steps. This vigilance shields buyers from inadvertent infringing product lines. We have developed novel purification steps and document every process variant to prove non-infringement if necessary. As patent cliffs approach, generic players need assurance about legal standing. Experience on the manufacturing side informs how we structure our documentation and verify compliance, removing later uncertainty for customers downstream in the value chain.
Nobody likes sudden gaps in supply. Behind the scenes, strong relationships with raw material suppliers, forged through years of two-way trust, give us leverage if bottlenecks strike upstream. Production planning is grounded in more than ERP forecasts—a real human tracks weather, political changes, and supplier line maintenance long before those feed into capacity plans. If necessary, we substitute solvents or intermediates from pre-qualified alternate sources, practicing changeover runs on-site long before supply emergencies force anyone’s hand.
Batch planning for Clonixic Acid involves more than scaling recipes. Operators cycle equipment through cleaning rotations tailored to avoid cross-lot contamination. Warehouse planning means product moves into secure, humidity-controlled space right after final packaging, slashing spoilage or degraded batches. Field engineers can adjust output tempo if immediate global conditions threaten shipping or import constraints. We don’t wait for shipping failures to develop alternate logistics channels, keeping our material on hand and accessible even during border disruptions or changes in customs policy.
Customers drive our process improvement agenda. Their phone calls, emails, and site visits provide uncensored feedback that leaves a stronger mark than any internal audit. Once, a long-standing customer pointed out issues with tablet friability linked to variation in particle morphology between lots. The investigation reached our synth operators, not just our technical managers. Operators compared historical batch logs, found temperature drift during one campaign, and introduced additional cooling controls. Persistent open channels mean problems receive action, not just polite responses.
No one in this business lasts long by ignoring customer needs. Every time a client flags a packaging problem—a torn liner, a leaky cap—we adapt procedures on our end. Over the years, those live corrections make the material better for the next buyer. Our Clonixic Acid doesn’t get shipped out and forgotten. We track customer usage, shelf life extension studies, and observe how finished products behave in varied climates and markets. Warehouse feedback gets routed to process update meetings so trends don’t go unseen.
Modern production tools certainly raise our output and reduce error rates, but reliance on dashboards doesn’t replace judgment or hands-on skill. Our synthesis teams know where to look for early warning signs—a faint color shift, unexpected viscosity, off-nominal filtration speed. Automated reports support their decision-making without dictating it. We run routine side-by-side pilot batches to test tweaks, applying both digital feedback and seasoned technician input.
Remote batch monitoring, predictive maintenance on pumps, and cloud-based QC reporting minimize unexpected downtime. Yet, it’s the seasoned shift leader who spots a questionable lot and signals for a second round of tests. Training at our facility runs deeper than classroom modules; new recruits learn from mentors who recite the story of each near-miss, explaining how it led to a permanent production or cleaning modification. These shared experiences get baked into how we approach both regular runs and troubleshooting emergencies.
Some producers hide behind secrecy, walling off information from buyers. We adopt the opposite stance, seeing joint problem-solving as a path to stronger partnerships. Insights, technical support, and trend notes get exchanged openly during audits, customer visits, and technical webinars. Sharing analytical data, field testing results, and process improvement tips has built trust strong enough to outlast economic dips and regulatory fluctuations. Our goal is to help users of our Clonixic Acid avoid costly failures—removing friction at every step from API sourcing to final product release.
We maintain technical bulletins and invite customer staff onto our production floor when a unique challenge pops up. If someone’s process uncovers an unexpected stability issue or novel application, we encourage two-way information flow rather than stonewalling. Many of our process improvements trace their roots to offhand remarks or on-the-ground troubleshooting, producing practical, bottom-line benefits for everyone in the value chain.
Direct comparison tests performed by users have shown us what truly separates our material from commodity imports or off-brand products. It comes down to reproducibility in assay, crystallinity, low levels of residual solvents, and a total absence of off-odors or discoloration. Specification conformity is a given, but field performance under stress—new tablet press speeds, challenging dissolution environments, or tight regulatory scrutiny—shows who paid attention to production details.
Buyers frequently report reduced waste and improved run rates moving to material sourced from us, because each shipment matches previous runs as closely as chemically possible. Regulatory inspections have gone smoother for finished product manufacturers able to trace Clonixic Acid CA-99 back several years through not only our paperwork, but also through in-line data logs and batch archive samples that we maintain indefinitely. We don’t just offer a material; we deliver consistency, insight, and direct accountability that short-term suppliers cannot.
Every ton of Clonixic Acid reflects environmental precautions and worker protection systems developed step by step. Regular audits ensure waste streams get routed through proper solvent recovery, neutralization, and emissions abatement. We maintain PPE standards not as a minimum box to check, but embedded in shop culture. Staff meetings routinely review new risks, update protocols, and report close calls so procedures get improved before accidents happen. Emergency drills run through worst-case scenarios—some learned the hard way—and everyone is expected to contribute feedback.
We accept responsibility for downstream impact, investing in monitoring tools that catch trace pollutants before they leave our grounds. Many environmental improvements, like solvent recycle loop upgrades and low-energy equipment retrofits, originated from floor-level staff suggestions after day-to-day observations. Protecting workers and the environment isn’t just a compliance exercise for us—it’s a pledge to those who depend on clean, safe materials and those who produce them.
To sum up a lifetime in chemical manufacturing, every kilo of Clonixic Acid reflects a collection of large and small choices—careful raw materials selection, practical process controls, attention to customer feedback, and constant improvement. In our view, no substitute exists for hands-on control, real-world learning, and an open line between our production team and every user of our products. We welcome scrutiny, technical challenge, and a cooperative approach that keeps us honest and keeps our material improving year after year. For those seeking high-grade Clonixic Acid with reliable traceability, documented performance, and support rooted in real production experience, our doors remain open—both in spirit and in practice.